[Form 4] STERIS plc Insider Trading Activity

Rhea-AI Filing Summary

STERIS plc (STE) Form 4: The company’s Senior Vice President, General Counsel and Secretary exercised 15,000 employee stock options at $69.72 per share on 11/11/2025 and sold 15,000 ordinary shares the same day at a weighted average price of $265.14 (range $265.00–$265.95). Following these transactions, the officer directly owned 33,669 shares as of 11/11/2025. Of these, 8,511 are restricted, with scheduled lapses through June 2028.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zangerle John Adam

(Last) (First) (Middle)

70 SIR JOHN ROGERSON'S QUAY

(Street)

DUBLIN 2 L2 D02 R296

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Sr. VP, Gen Counsel, and Sec.

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/11/2025		M		15,000	A	$69.72	48,669(1)	D
Ordinary Shares	11/11/2025		S		15,000	D	$265.14(2)	33,669(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$69.72	11/11/2025		M			15,000	(3)	06/01/2026	Ordinary Shares	15,000	$0	0	D

Explanation of Responses:

1. As of November 11, 2025, 8,511 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,157 on June 1, 2026; 846 on June 2, 2026; 1,252 on June 3, 2026; 1,376 on June 4, 2026; 1,252 on June 3 2027; 1,376 on June 4, 2027 and 1,252 on June 5, 2028.

2. Price reflects a weighted average sale price for multiple transactions ranging from $265.00 to $265.95 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.

3. This option to purchase 15,000 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 15,000 ordinary shares for $69.72 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.

Remarks:

	/s/ John P. Ubbing, Authorized Representative under Power of Attorney	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did STERIS (STE) disclose in this Form 4?

An officer exercised 15,000 options at $69.72 and sold 15,000 shares at a weighted average of $265.14 on 11/11/2025.

How many STERIS shares does the reporting person own after the transactions?

Direct ownership was 33,669 shares as of 11/11/2025.

Were the shares sold in multiple trades and at what prices?

Yes. The weighted average sale price was $265.14, with individual trades from $265.00 to $265.95.

What was the option exercise price and type?

Employee stock option with a $69.72 exercise price; 15,000 options were exercised on 11/11/2025.

Are any of the owned STERIS shares restricted?

Yes. 8,511 shares were restricted as of 11/11/2025, with lapses scheduled through June 2028.

What is the option’s background and status post-transaction?

The 15,000-share option, fully vested, stemmed from STERIS’s 2019 redomiciliation; 0 derivative securities remained after exercise.